Growing Clinical Partnerships Renalytix has recently expanded its US footprint by signing three new clinical partnerships across New York, Florida, and Tennessee, indicating increasing adoption of its FDA-approved kidney risk testing platform. This presents an opportunity to approach additional healthcare providers in these regions for potential collaborations.

Strong Market Demand The company's quarterly revenue increased by 20 percent, driven by a record number of billable tests, demonstrating strong market demand for its artificial intelligence-enabled diagnostics. Targeting clinics and health systems looking to enhance early kidney disease detection could prove fruitful.

Strategic US Expansion Renalytix is actively raising capital to fund its US expansion strategy, including a recent £4.5 million equity raise. Engaging with healthcare organizations and providers in the US market could help position your offerings alongside their ongoing growth efforts.

Innovative Technology Focus As a leader in bioprognosis for kidney health, Renalytix leverages advanced AI and proprietary diagnostics to assess disease progression risk early. Partnering with or integrating solutions into Renalytix’s platform can enable providers to improve patient outcomes and drive value-based care.

International Collaborations Renalytix has begun expanding beyond the US through collaborations like the one with Steno Diabetes Center in Copenhagen, focusing on precision medicine for diabetes-related kidney disease. This international footprint creates avenues for new sales channels in Europe and beyond.